Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2026 R&D 100 Award Winners
    • 2026 Professional Award Winners
    • 2026 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • Subscribe
    • Video
    • Webinars
    • PharmSci360
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Isomorphic Labs raises $5 billion in biotech’s biggest venture round

By Brian Buntz | November 17, 2026

Isomorphic Labs illustration of translucent pink molecular surfaces around a green double helix against a peach background

Credit: Isomorphic Labs

Six months after raising $2.1 billion, Alphabet-controlled Isomorphic Labs has secured another $5 billion to expand its AI drug-design engine and advance its first therapeutic programs toward human trials. Greenoaks and Sequoia Capital co-led the Series C round, announced Nov. 17, for the company led by Nobel laureate Demis Hassabis.

BioSpace calls the financing the largest venture round in biotech history, surpassing the $3 billion Altos Labs raised at its 2022 launch. It also more than doubles Isomorphic’s $2.1 billion Series B from May. For comparison, fellow AI drug developer Xaira Therapeutics launched in April 2024 with more than $1 billion in committed capital. BioSpace counts at least $7.7 billion raised by Isomorphic since March 2025.

Andreessen Horowitz and several other new investors joined the round. Alphabet invested again, and every existing backer took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Alphabet holds 75% or more of Isomorphic’s shares and voting rights, according to UK Companies House records that reflect a June share allotment. Hassabis, Isomorphic’s CEO since its 2021 spinout from DeepMind, stepped down as Google DeepMind’s CEO in August to become its chairman and Alphabet’s chief scientist. Bloomberg had reported Nov. 4 that the company was in talks to raise about $5 billion at a valuation of roughly $50 billion.

Isomorphic says it will spend the money maturing IsoDDE, its proprietary drug design engine, which it describes as a suite of simulation models that work across therapeutic areas and drug modalities. The company also plans to build what it calls global infrastructure for AI-led bioengineering, along with translational and clinical development infrastructure for moving candidates into trials. “This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients,” Hassabis said in the release.

Isomorphic keeps its newest models closer than DeepMind kept the first three AlphaFold generations. The two companies developed AlphaFold 3 together and published it in May 2024 with access through the web-based AlphaFold Server, then released its code and, under non-commercial terms, its model weights that November. Isomorphic described IsoDDE on Feb. 10 in a technical report without code, weights or training details, and the company has no plans to reveal the “secret sauce,” Nature reported.  Isomorphic puts its models to work through its internal drug programs and partnerships with companies like Eli Lilly, Novartis and Johnson & Johnson. “We’re not selling access to the models, we’re not selling tokens or API access,” President Max Jaderberg said at Bloomberg Tech in London on Nov. 2.

The round adds to a fast-rising flow of money into AI drug discovery. Investor funding for AI-enabled drug discovery more than doubled from $4.1 billion in 2023 to $8.4 billion in 2025, and headline AI deal value among the top 20 drugmakers doubled to $29.5 billion in 2025, McKinsey reported in September, as R&D World covered. Drugmakers paid 2% of that 2025 deal value up front and tied 60% to 90% to later clinical and commercial milestones. Drug discovery startups have raised a record $23.2 billion so far in 2026, according to Dealroom figures cited by CNBC.

Isomorphic’s milestones remain preclinical. The company says its models are producing positive preclinical results in internal oncology and immunology programs and with partners, “setting the stage for clinical entry.” At the same London event, Jaderberg described the programs as “deep in pre-clinical development,” R&D World reported. Hassabis said at Davos in January that Isomorphic expected its first clinical trials by the end of 2026, Reuters reported. That target replaced his earlier goal of AI-designed drugs in trials by the end of 2025, and it is now six weeks away.

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

QuEra exec on AI-designed quantum circuits, and why he doesn’t expect drug discovery to be quantum’s first big win
Clipboard, woman and scientist writing in laboratory for medical research on cancer drug trial. Checklist, investigation and female biologist with clinic protocol development for pharmaceutical study.
Pharma is pouring billions into AI. The biggest returns may take years to prove.
As AI bubble talk grows, Dwarkesh Patel predicts recursive self-improvement will set off an AI research explosion
Elsevier survey: 63% of corporate R&D staff say a key decision rested on flawed data
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.

R&D World Digital Issues

Fall 2026 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

R&D 100 Awards
Research & Development World
  • Subscribe to R&D World Magazine
  • Sign up for R&D World’s newsletter
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2026 R&D 100 Award Winners
    • 2026 Professional Award Winners
    • 2026 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • Subscribe
    • Video
    • Webinars
    • PharmSci360
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE